Endocyte: Clinical Trials

17 trials sponsored by Endocyte, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 2 active not recruiting, 2 terminated, 1 withdrawn. 17 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 217Completed 12, Active not recruiting 2, Terminated 2, Withdrawn 1
Phase 11Active not recruiting 1

Follow Endocyte: new trials by email

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
Lu-PSMA, Enzalutamide - Metastatic Castration-Resistant Prostate Cancer
Phase 2Active not recruitingAustralian and New Zealand Urogenital and Prostate Cancer Trials Group1622020-08-172026-06-22
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
177Lu-PSMA-617 - Prostatic Neoplasms
Phase 1 / Phase 2Active not recruitingPeter MacCallum Cancer Centre, Australia202020-08-062024-11-08
A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
177Lu-PSMA617, Cabazitaxel - Cancer of the Prostate, Metastatic Cancer
Phase 2CompletedAustralian and New Zealand Urogenital and Prostate Cancer Trials Group2012018-01-292022-06-13
Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
177Lu-PSMA-617 - Metastatic Castration Resistant Prostate Cancer
Phase 2TerminatedEndocyte712017-07-122021-03-24
Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
Vintafolide 2.5 mg, Paclitaxel 80 mg/m^2, Etarfolatide - Breast Neoplasms
Phase 2WithdrawnEndocyte2014-04-012014-12-19
Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer
EC145, EC145 + Docetaxel, Docetaxel - Non Small Cell Lung Cancer
Phase 2CompletedEndocyte2032011-03-012021-04-01
Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
EC145 - Solid Tumors
Phase 2CompletedEndocyte12009-12-312021-04-08
Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)
Vintafolide, pegylated liposomal doxorubicin (PLD), EC20 - Ovarian Cancer
Phase 2CompletedEndocyte1622008-09-012015-01-07
Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)
Vintafolide, Ertafolide - Ovarian Cancer, Endometrial Cancer
Phase 2CompletedEndocyte492007-08-012015-01-07
Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
Vintafolide, Etarfolatide - Adenocarcinoma of the Lung
Phase 2CompletedEndocyte432007-08-012015-02-27
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC) - Renal Cell Carcinoma
Phase 2TerminatedEndocyte122007-06-012012-03-08
FolateScan in Autoimmune Disease
FolateScan (Technetium Tc 99mEC20) - Rheumatoid Arthritis, Osteoarthritis
Phase 2CompletedMayo Clinic752006-09-012010-04-16
Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma
Technetium Tc 99m EC20 - Metastatic Renal Cell Carcinoma
Phase 2CompletedEndocyte1502003-11-012023-07-25
Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
Tc 99m EC20 - Recurrent or Metastatic Cancer, Head and Neck Cancer
Phase 2CompletedEndocyte402003-08-012023-06-22
Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma
Tc 99m EC20 - Ovarian Carcinoma, Recurrent Endometrial Carcinoma
Phase 2CompletedEndocyte162003-08-012023-06-22
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
Technetium Tc 99m EC20 - Pituitary Tumors
Phase 2CompletedEndocyte402002-09-012023-06-22
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma
Tc 99m EC20 - Metastatic Renal Cell Carcinoma
Phase 2CompletedEndocyte402002-08-012023-06-22

Conditions studied

Neoplasms (5)  ·  Adenocarcinoma (3)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Carcinoma, Renal Cell (3)  ·  Neoplasm Metastasis (3)  ·  Ovarian Neoplasms (3)  ·  Endometrial Neoplasms (2)  ·  Prostatic Neoplasms (2)  ·  Adenocarcinoma of Lung (1)  ·  Arthritis, Rheumatoid (1)  ·  Breast Neoplasms (1)  ·  Crohn Disease (1)  ·  Head and Neck Neoplasms (1)  ·  Lupus Erythematosus, Systemic (1)  ·  Multiple Sclerosis (1)

Interventions

EC145 (6)  ·  Pluvicto (3)  ·  technetium 99m etarfolatide (3)  ·  Docetaxel (1)  ·  Folic Acid (1)  ·  GPI0100 (1)  ·  Interferon-alpha (1)  ·  Interleukin-2 (1)  ·  Introns (1)  ·  Paclitaxel (1)  ·  Premedication (1)  ·  aldesleukin (1)  ·  cabazitaxel (1)  ·  enzalutamide (1)  ·  fluorescein isothiocyanate-keyhole limpet hemocyanin (1)

Countries

United States (7)  ·  Australia (3)

Top investigators

Binh Nguyen, MD, PhD (2)  ·  Declan Murphy (1)  ·  Eric L Matteson, M.D., M.P.H. (1)  ·  John Violet (1)  ·  Louise Emmett, MBBS, FRACP (1)  ·  Michael Hofman, A/Prof (1)  ·  Michael S Hofman (1)  ·  Nelson M Oyesiku, MD, PhD (1)  ·  Nelson Oyesiku, MD (1)  ·  Richard A Messmann, MD, MHS, BSc (1)  ·  Siu-Long Yao (1)  ·  Val J Lowe, MD (1)

Results publications

PMID 18952896, PMID 24127448, PMID 24667717, PMID 31595044, PMID 33581798, PMID 34246328, PMID 34373282, PMID 36261050, PMID 36350899, PMID 37407274, PMID 37891072, PMID 38043558, PMID 38621400, PMID 39956124, PMID 40425844, PMID 40752515, PMID 41956861, PMID 41986500, PMID 42048586